Lyell Immunopharma (LYEL) EPS (Weighted Average and Diluted): 2020-2025
Historic EPS (Weighted Average and Diluted) for Lyell Immunopharma (LYEL) over the last 5 years, with Sep 2025 value amounting to -$2.13.
- Lyell Immunopharma's EPS (Weighted Average and Diluted) rose 38.79% to -$2.13 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.32, marking a year-over-year increase of 170.84%. This contributed to the annual value of -$1.31 for FY2024, which is 40.86% down from last year.
- Latest data reveals that Lyell Immunopharma reported EPS (Weighted Average and Diluted) of -$2.13 as of Q3 2025, which was up 26.30% from -$2.89 recorded in Q2 2025.
- In the past 5 years, Lyell Immunopharma's EPS (Weighted Average and Diluted) registered a high of $10.52 during Q4 2024, and its lowest value of -$3.59 during Q2 2024.
- Over the past 3 years, Lyell Immunopharma's median EPS (Weighted Average and Diluted) value was -$0.26 (recorded in 2023), while the average stood at -$0.27.
- Within the past 5 years, the most significant YoY rise in Lyell Immunopharma's EPS (Weighted Average and Diluted) was 5,360.00% (2024), while the steepest drop was 1,640.00% (2024).
- Quarterly analysis of 5 years shows Lyell Immunopharma's EPS (Weighted Average and Diluted) stood at -$0.18 in 2021, then soared by 83.33% to -$0.03 in 2022, then plummeted by 566.67% to -$0.20 in 2023, then skyrocketed by 5,360.00% to $10.52 in 2024, then surged by 38.79% to -$2.13 in 2025.
- Its last three reported values are -$2.13 in Q3 2025, -$2.89 for Q2 2025, and -$0.18 during Q1 2025.